Online Course to Update Allergists and Dermatologists on Latest in Atopic Dermatitis Management
Atopic dermatitis (AD) is a chronic, relapsing inflammatory condition that is estimated to afflict more than 26 million people in the United States. If left uncontrolled, AD can have a significant impact on patient health and quality of life (QoL), and approximately one-third of AD patients have severe disease that requires systemic treatment directed at controlling immune responses.
To familiarize clinicians with newer therapies and current practice in management of moderate to severe atopic dermatitis, the Potomac Center for Medical Education and Rockpointe have launched a free CME-certified/ABIM MOC and MIPS-eligible webcourse that is available until Feb. 8, 2023.
In recent years, novel therapies targeting the underlying pathophysiology of AD have been approved, with many more emerging, but many clinicians lack familiarity with these agents as well as related mechanisms of action and safety and efficacy profiles. Furthermore, clinicians often underestimate AD disease severity and the impact on patients’ quality of life, leading to undertreatment. Targeted Therapies For Atopic Dermatitis: On the Cusp of a Golden Era? is an hour-long program that aims to provide allergists and dermatologists with up-to-date information on management of moderate to severe AD, including the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence-based use of newer targeted therapies, and how emerging therapies may impact AD management in the near term.
At the conclusion of this activity, participants should be able to:
· Describe the role of type 2 inflammatory processes in the pathophysiology of atopic dermatitis.
· Utilize evidence-based disease assessment tools to identify patients with moderate to severe AD.
· Implement shared decision-making into routine practice to incorporate patient goals and needs into multidisciplinary AD action plans.
· Evaluate the safety and efficacy of current and emerging targeted therapies for moderate to severe AD.
This program is CME-certified, and ABIM MOC and MIPS-eligible and qualifies the participant for 1 hour of credit. There is no fee for this activity, which is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals and is jointly provided by the Potomac Center for Medical Education and Rockpointe. To receive credit, participants must take the pre-test, view the activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. Participants may take the post-test multiple times. Full accreditation information will be provided to participants prior to starting the course.
Through effective accredited continuing education, Rockpointe, a leader in educational programming with more than 26 years of experience, strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
To view Targeted Therapies for Atopic Dermatitis: On the Cusp of a Golden Era?, click here.